Profusa Secures $100M Equity Line, Eyes Bitcoin for Capital Deployment

TL;DR

**Profusa's $100M equity line is a double-edged sword, providing capital but signaling potential dilution and a highly speculative Bitcoin investment strategy that could deter traditional biotech investors.**

AI Summary

Profusa, Inc. (formerly NorthView Acquisition Corporation) completed a business combination on July 11, 2025, merging with Profusa, Inc., a California corporation, to become a wholly-owned subsidiary. The company is developing biointegrated sensors, with its Lumee Oxygen Platform already offered in the European Union for monitoring tissue oxygen levels in conditions like peripheral artery disease and chronic wounds. A key focus is the Lumee Glucose Platform, a continuous glucose monitor designed for long-term use with a single injection. On July 28, 2025, Profusa entered into a Purchase Agreement with Ascent Partners Fund LLC, allowing Profusa to sell up to $100,000,000 in common stock to Ascent over 36 months. The purchase price for these shares will be 97% of the lowest volume-weighted average price during a valuation period, subject to a $5,000,000 maximum per closing and a 19.9% exchange cap unless stockholder approval is obtained or the average price exceeds $0.68 per share. Profusa will not receive proceeds from Ascent's resale of 8,970,830 shares, but expects to use any proceeds from direct sales to Ascent for Bitcoin purchases. The company's common stock trades on Nasdaq under the symbol "PFSA" and closed at $0.53 per share on August 5, 2025.

Why It Matters

This S-1/A filing reveals Profusa's strategic shift towards a committed equity facility with Ascent Partners Fund LLC, providing up to $100,000,000 in potential capital. For investors, this facility offers a funding mechanism for Profusa's biointegrated sensor development, particularly the Lumee Glucose Platform, but also introduces significant dilution risk given the 97% VWAP pricing and potential for sales below the $0.68 exchange cap threshold. The stated intent to use proceeds for Bitcoin purchases is highly unusual for a medical device company and introduces substantial speculative risk, differentiating Profusa from traditional competitors in the CGM space like Dexcom or Abbott. Employees and customers might see this as a sign of long-term funding, but the Bitcoin strategy could raise questions about financial stability and focus.

Risk Assessment

Risk Level: high — The risk level is high due to several factors: the company's reliance on a committed equity facility for funding, which can lead to significant dilution as shares are sold at 97% of the lowest VWAP; the potential for sales below the $0.68 per share Nasdaq threshold, triggering the 19.9% exchange cap unless stockholder approval is obtained; and the highly speculative stated use of proceeds for 'the purchase of Bitcoin,' which introduces extreme volatility and market risk unrelated to its core medical device business.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Profusa's long-term viability given the significant dilution potential from the equity facility and the highly speculative plan to use capital for Bitcoin. Consider the company's burn rate and the impact of potential share price declines on the effectiveness of the $100,000,000 facility. Monitor future filings for details on Bitcoin purchases and their impact on financial stability.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$1,700,000

total Debt

$0

net Income

$-15,800,000

eps

$-0.79

gross Margin

N/A

cash Position

$1,200,000

revenue Growth

N/A

Key Numbers

• $100,000,000 — Maximum Aggregate Purchase Price (Potential gross proceeds from sales of common stock to Ascent Partners Fund LLC)
• 8,970,830 — Shares of Common Stock (Total shares registered for resale by Ascent Partners Fund LLC)
• 97% — Purchase Price Discount (Percentage of lowest VWAP at which Profusa may sell shares to Ascent)
• 19.9% — Exchange Cap (Maximum percentage of outstanding common stock issuable without stockholder approval under Nasdaq rules)
• $0.53 — Last Sale Price (Profusa's common stock price on Nasdaq as of August 5, 2025)
• 36 months — Purchase Agreement Term (Duration over which Profusa may elect to sell shares to Ascent)
• 9.99% — Beneficial Ownership Limitation (Maximum percentage of outstanding shares Ascent can beneficially own)
• July 11, 2025 — Business Combination Date (Date Profusa, Inc. (CA) merged with NorthView Acquisition Corporation)
• July 28, 2025 — Purchase Agreement Date (Date Profusa entered into the Purchase Agreement with Ascent)
• 900,000 — Commitment Warrant Shares (Shares issuable upon exercise of warrants issued to Ascent)

Key Players & Entities

• Profusa, Inc. (company) — Registrant and developer of biointegrated sensors
• NorthView Acquisition Corporation (company) — Former name of Profusa, Inc. before business combination
• Ascent Partners Fund LLC (company) — Selling Stockholder and counterparty to the Purchase Agreement
• Ben C. Hwang (person) — Chief Executive Officer of Profusa, Inc.
• Ralph V. De Martino, Esq. (person) — Legal counsel from ArentFox Schiff LLP
• Marc Rivera, Esq. (person) — Legal counsel from ArentFox Schiff LLP
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• $100,000,000 (dollar_amount) — Maximum aggregate gross proceeds from sales to Ascent
• $0.53 (dollar_amount) — Last sale price of common stock on Nasdaq on August 5, 2025
• $0.68 (dollar_amount) — Nasdaq threshold price for Exchange Cap waiver

FAQ

Risk Factors

• Reliance on Committed Equity Facility [high — financial]: Profusa has entered into a $100,000,000 common stock purchase agreement with Ascent Partners Fund LLC. The company may sell shares at 97% of the lowest volume-weighted average price during a valuation period, subject to certain limitations. This structure can lead to significant dilution and may result in the company receiving less than the expected proceeds per share.
• FDA Approval Pathway Uncertainty [high — regulatory]: Profusa's Lumee Glucose Platform requires FDA approval for commercialization in the United States. The development and regulatory approval process for novel medical devices is lengthy, complex, and expensive, with no guarantee of success. Delays or failure to obtain approval could materially impact the company's ability to generate revenue.
• Competition in Continuous Glucose Monitoring [medium — market]: The continuous glucose monitoring (CGM) market is highly competitive, with established players like Dexcom and Abbott. Profusa's Lumee Glucose Platform must differentiate itself through performance, cost, or unique features to gain market share against these entrenched competitors.
• Manufacturing and Scalability Challenges [medium — operational]: Scaling up manufacturing for biointegrated sensors, particularly for a novel product like the Lumee Glucose Platform, presents significant operational hurdles. Ensuring consistent quality, meeting demand, and managing supply chain complexities will be critical for successful commercialization.
• Burn Rate and Need for Future Funding [high — financial]: As a development-stage company, Profusa has a history of operating losses and significant cash burn. The company will likely require substantial additional capital to fund its ongoing research and development, clinical trials, regulatory submissions, and commercialization efforts.
• Intellectual Property Protection [medium — legal]: Profusa's success depends on its ability to protect its proprietary technology through patents and trade secrets. Infringement by competitors or challenges to its intellectual property rights could severely impact its competitive position and future profitability.

Industry Context

Profusa operates in the rapidly evolving medical device sector, specifically focusing on biointegrated sensors. The company aims to disrupt the continuous glucose monitoring (CGM) market, which is currently dominated by established players with existing technologies. Key industry trends include the increasing demand for non-invasive or minimally invasive monitoring solutions and the integration of sensor data with digital health platforms.

Regulatory Implications

Profusa's success is heavily dependent on navigating complex regulatory pathways, particularly with the FDA for its Lumee Glucose Platform. Obtaining approval for novel medical devices is a rigorous and time-consuming process that requires extensive clinical validation and adherence to strict quality standards. Failure to secure regulatory clearance could prevent market entry in key regions like the United States.

What Investors Should Do

1. Monitor FDA approval progress for the Lumee Glucose Platform.
2. Analyze the impact of the Ascent Partners equity facility on share dilution.
3. Assess competitive positioning against established CGM players.
4. Evaluate the company's cash burn rate and future funding needs.

Key Dates

• 2025-07-11: Business Combination Completion — Profusa, Inc. (CA) merged with NorthView Acquisition Corporation, becoming a publicly traded entity under the Profusa, Inc. name.
• 2025-07-28: Purchase Agreement with Ascent Partners Fund LLC — Established a committed equity facility allowing Profusa to sell up to $100,000,000 in common stock over 36 months, providing potential future capital but also dilution risk.
• 2025-08-05: Common Stock Last Sale Price — The stock closed at $0.53 per share, indicating a low valuation and potential for significant dilution under the Ascent agreement.

Glossary

Biointegrated Sensors

Medical devices designed to be implanted or integrated with biological systems to monitor physiological parameters. (This is Profusa's core technology area, forming the basis of their product development.)

Lumee Oxygen Platform

Profusa's existing product for monitoring tissue oxygen levels, currently available in the EU. (Represents Profusa's current commercial product and a revenue stream, albeit limited.)

Lumee Glucose Platform

Profusa's planned continuous glucose monitor for long-term use, requiring FDA approval. (This is Profusa's key future product with significant market potential but also substantial regulatory and development hurdles.)

Committed Equity Facility

An agreement where an investor commits to purchase shares of a company's stock over a period, typically at a discount to market price. (The agreement with Ascent Partners Fund LLC provides potential funding but at terms that can be dilutive to existing shareholders.)

Volume-Weighted Average Price (VWAP)

The average price of a security over a given period, weighted by the volume of trades at each price level. (The purchase price under the Ascent agreement is tied to the VWAP, making the timing of sales critical.)

Exchange Cap

A limit on the percentage of a company's outstanding shares that can be issued in a single transaction or over a period without shareholder approval, often dictated by stock exchange rules. (The 19.9% cap impacts how quickly Profusa can utilize the committed equity facility without seeking additional shareholder consent.)

Year-Over-Year Comparison

This S-1/A filing represents Profusa's transition to a public company following a business combination. As such, direct year-over-year comparisons of financial metrics like revenue, margins, and net income are not applicable in the traditional sense. The filing primarily focuses on the company's business plan, technology, risks, and its new financing arrangement with Ascent Partners Fund LLC, which will be crucial for future operations and growth.

Key Financial Figures

• $0.0001 — 0 shares of our Common Stock, par value $0.0001 per share ("the Common Stock"), by Asce
• $0.01 — ment Warrants have an exercise price of $0.01 and may be exercised for cash or, if at
• $100,000,000 — ckholder. However, we may receive up to $100,000,000 in aggregate gross proceeds under the P
• $0.53 — eported on the Nasdaq Global Market was $0.53 per share. We are a "smaller reportin
• $5,000,000 — Closing is limited to the lower of (a) $5,000,000 or (b) 100% of the average daily traded
• $0.68 — se Agreement, if any, equals or exceeds $0.68 per share (representing the lower of (a
• $30,000 — ts Agreement in an amount not to exceed $30,000 upon our execution of the Purchase Agre
• $0 — an assumed purchase price per share of $0.68, representing the closing sale price
• $5.5 million — 25, we would only receive approximately $5.5 million in aggregate gross proceeds from the sa

Filing Documents

• ea0251811-02.htm (S-1/A) — 12841KB
• ea025181102ex23-1_profusa.htm (EX-23.1) — 2KB
• ea025181102ex23-2_profusa.htm (EX-23.2) — 2KB
• tprofusa_logo.jpg (GRAPHIC) — 85KB
• timage_001.jpg (GRAPHIC) — 255KB
• timage_002.jpg (GRAPHIC) — 300KB
• timage_003.jpg (GRAPHIC) — 336KB
• timage_004.jpg (GRAPHIC) — 569KB
• timage_005.jpg (GRAPHIC) — 202KB
• timage_006.jpg (GRAPHIC) — 368KB
• timage_007.jpg (GRAPHIC) — 260KB
• timage_008.jpg (GRAPHIC) — 631KB
• 0001213900-25-079401.txt ( ) — 46934KB
• ck0001859807-20250630.xsd (EX-101.SCH) — 137KB
• ck0001859807-20250630_cal.xml (EX-101.CAL) — 77KB
• ck0001859807-20250630_def.xml (EX-101.DEF) — 796KB
• ck0001859807-20250630_lab.xml (EX-101.LAB) — 1065KB
• ck0001859807-20250630_pre.xml (EX-101.PRE) — 806KB
• ea0251811-02_htm.xml (XML) — 8881KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 72 THE COMMITTED EQUITY FACILITY 73

USE OF PROCEEDS

USE OF PROCEEDS 79 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 80 DIVIDEND POLICY 94 MARKET INFORMATION 95

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 96

BUSINESS

BUSINESS 108 MANAGEMENT 134

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 139

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 141 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 143 SELLING STOCKHOLDER 147 PLAN OF DISTRIBUTION 149

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 153 LEGAL MATTERS 157 EXPERTS 157 WHERE YOU CAN FIND MORE INFORMATION 157 INDEX TO FINANCIAL INFORMATION F-1 You should rely only on the information contained in this prospectus or any amendment or supplement to this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus or any amendment or supplement to this prospectus. Neither we nor the Selling Stockholder take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus or any amendment or supplement to this prospectus. The information in this prospectus or any amendment or supplement to this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any amendment or supplement to this prospectus, as applicable, or any sale of the securities offered by this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States: The Selling Stockholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. i Table of C

View Full Filing

View this S-1/A filing on SEC EDGAR